CSPC

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, March 12, 2024
MUC, Human, Biotechnology, CSPC, Drug discovery, Carcinoma, Cervical cancer, Rash, Patient, MMAE, Tumor microenvironment, Peripheral neuropathy, IND, PH1b, Insulin resistance, Investment, Investigational New Drug, Therapy, CB1, ATM, Safety, Liraglutide, CMO, FDA, PD-1, Pharmaceutical industry

We expect to dose the first patient in our US Ph1 study in March 2024.

Key Points: 
  • We expect to dose the first patient in our US Ph1 study in March 2024.
  • For CRB-601, the FDA cleared our Investigational New Drug (“IND”) application in January 2024, and we expect to dose the first patient this summer.
  • The Company presented CRB-913 pre-clinical data at Obesity Week as an oral presentation and as a late breaking poster in October 2023.
  • The Company is currently conducting IND enabling studies and expects to file an IND in the fourth quarter of 2024.

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

Retrieved on: 
Wednesday, February 28, 2024
Therapy, AstraZeneca, CMO, CD25, Biotechnology, Roche, Neoplasm, Physician, Obesity, Amgen, Icon, Pharmaceutical medicine, Bladder cancer, Royal college, ADC, Antibody, NHS, Safety, CB1, CSPC, Patient, CD137, Faculty, Partnership, Pharmaceutical industry

NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company’s Chief Medical Officer (CMO).

Key Points: 
  • NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company’s Chief Medical Officer (CMO).
  • Additionally, Dr. Smethurst will help guide strategic development of CRB-913, the Company’s highly peripherally restricted CB1 inverse agonist for the treatment of obesity.
  • “We are pleased to welcome Dominic to the Corbus team and look forward to benefitting from his experience in developing novel oncology therapeutics including ones that specifically target Nectin-4", said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.
  • Previously, Dr. Smethurst worked as a consultant advising biopharma companies, providing guidance on clinical development strategies and licensing projects.

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

Retrieved on: 
Friday, January 26, 2024
MMAE, Neoplasm, Patient, PST, Yale school, CSPC, Shijiazhuang Pharma Group, Yale School of Medicine, ADC, Rash, Peripheral neuropathy, Brentuximab vedotin, ASCO, MUC, Poster, Society, Cervical cancer, Safety, EV, GU, Corbus, Urology, Tab, Trial of the century, Pharmaceutical industry

The poster is titled Phase 1 Dose Escalation of SYS6002(CRB-701), a Next Generation Nectin-4 Targeting Antibody Drug Conjugate by DingWei Ye, et al and is being presented today at the poster session between 11:30 am-1pm PST.

Key Points: 
  • The poster is titled Phase 1 Dose Escalation of SYS6002(CRB-701), a Next Generation Nectin-4 Targeting Antibody Drug Conjugate by DingWei Ye, et al and is being presented today at the poster session between 11:30 am-1pm PST.
  • The poster will also be available on the Corbus website at the start of the poster presentation.
  • We are grateful to CSPC for the work that has gone into conducting this ongoing study and to the clinicians and study participants."
  • Dose escalation and expansion are ongoing and additional data presentations are planned for later this year.

Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU

Retrieved on: 
Tuesday, January 23, 2024
Patient, Maxima and minima, PST, Carcinoma, CSPC, Shijiazhuang Pharma Group, ADC, Poster, ASCO, MUC, Society, Cervical cancer, Plasma, Triple-negative breast cancer, Safety, EV, Index, TNBC, CRC, Phase, Colorectal cancer, Data, MTD, Pharmaceutical industry

The data referred to in the abstract dates to September of 2023; the upcoming presentation will include data as of December 2023.

Key Points: 
  • The data referred to in the abstract dates to September of 2023; the upcoming presentation will include data as of December 2023.
  • ASCO GU will be held January 25-27, 2024 in San Francisco, CA and online.
  • Additionally, by administering SYS6002 (CRB-701) on a Q3W schedule there is an opportunity to increase clinical convenience and patient compliance.
  • Continued development of SYS6002 (CRB-701) as both a monotherapy and in combination is planned both in China (CSPC), U.S. and Europe (Corbus Pharmaceuticals Holdings, Inc.).

Bayer Reveals Latest Prostate Cancer Data at 2024 ASCO GU Cancers Symposium

Retrieved on: 
Wednesday, January 17, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, BCR, CSPC, Prostate cancer, Hospital, Metastasis, ASCO, EBRT, Systematic review, Safety, Society, Docetaxel, Observational study, ADT, Phase, Cancer, Medical imaging

Bayer will present new data across its prostate cancer portfolio at the upcoming American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place January 25-27, 2024 in San Francisco, California.

Key Points: 
  • Bayer will present new data across its prostate cancer portfolio at the upcoming American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place January 25-27, 2024 in San Francisco, California.
  • These presentations underscore Bayer’s commitment to advance prostate cancer care.
  • NUBEQA® (darolutamide) data includes post hoc sensitivity analyses from the Phase III ARASENS trial, evaluating overall survival (OS) with NUBEQA and androgen deprivation therapy (ADT) and docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC) patients accounting for subsequent therapy.
  • Abstract title: Safety outcomes in patients with metastatic castration-resistant prostate cancer treated with radium-223 following external beam radiation therapy: REASSURE US subset

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU

Retrieved on: 
Monday, December 18, 2023
CSPC, Conference, AACR, Food, ASCO, Carcinoma, Society, Brentuximab vedotin, Patient, ADC, MMAE

NORWOOD, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced that the Phase 1, first-in-human clinical data from a dose escalation study being carried out by its partner CSPC in China with CRB-701 (SYS6002) has been accepted for presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) , to be held January 25-27, 2024 in San Francisco, CA and online.

Key Points: 
  • NORWOOD, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced that the Phase 1, first-in-human clinical data from a dose escalation study being carried out by its partner CSPC in China with CRB-701 (SYS6002) has been accepted for presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) , to be held January 25-27, 2024 in San Francisco, CA and online.
  • CRB-701 (SYS6002) is a next-generation antibody-drug-conjugate (ADC) targeting nectin-4, that contains a third generation, site-specific, cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload.
  • Pre-clinical data demonstrating differentiation from enfortumab vedotin was recently presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
  • Nectin-4 is a clinically validated, tumor-associated antigen in urothelial cancer.

CSPC Assists Evacuees in their Battle against Trauma

Retrieved on: 
Monday, December 11, 2023
Attention, Life, History, Multimedia, Light, Fear, MSW, Trauma, CSPC, Military personnel, Government, Nursing, Arabic

In the center of Kiryat Shmona, just 1.1 miles from the Lebanon border, over 25,000 residents have been scattered among 200 hotels far from their homes at the Community Stress Prevention Center (CSPC).

Key Points: 
  • In the center of Kiryat Shmona, just 1.1 miles from the Lebanon border, over 25,000 residents have been scattered among 200 hotels far from their homes at the Community Stress Prevention Center (CSPC).
  • Since the start of the war, 150 CSPC staff have been working around the clock with the evacuees in the hotels, witnessing their fear and doing everything they can to support children, adults, and the military personnel through advanced trauma treatment methods.
  • CSPC also provides a mental health hotline in Arabic for the Arabic society in order to provide the necessary impact.
  • The CSPC currently wishes to spread the unique therapeutic methods it has developed and the resilience-focused rehabilitation system as widely as possible, in many populations".

Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 7, 2023
Rimonabant, NSCLC, Food, Biomarker, Doctor of Philosophy, CB1, Breast cancer, University of Virginia Cancer Center, SITC, The Obesity Society, Head, CSPC, FACP, Human, Therapeutic index, Cleavage, Yale School of Medicine, Society for Immunotherapy of Cancer, Mouse, DIO, Immunotherapy, University, Hand, Investment, Patient, Monoclonal antibody, Food and Drug Administration Amendments Act of 2007, Plasma, Conference, Liraglutide, Development, ADC, Brain, Insulin resistance, Society, AACR, IND, Manuscript, Poster, MMAE, Semaglutide, Tumor microenvironment, Carcinoma, Mab, Neck, Medical imaging, Vaccine, Soft drink, Pharmaceutical industry, Corbus, MD, Obesity

“The third quarter was a productive period for Corbus as data was presented for each of our three programs at relevant scientific conferences” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.

Key Points: 
  • “The third quarter was a productive period for Corbus as data was presented for each of our three programs at relevant scientific conferences” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.
  • Finally, we presented the first ever comprehensive data on CRB-913, our highly peripherally restricted cannabinoid type-1 receptor (CB1) inverse agonist.
  • Early clinical experience will be shared in Q1 2024, which will coincide with the initiation of a U.S./EU trial by Corbus.
  • Corbus presented two posters at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) held on November 1 - 5, 2023.

Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701

Retrieved on: 
Monday, October 16, 2023
CSPC, Plasma, AACR, Cancer, Half-life, EV, Therapy, MMAE, ADC, Conference, Patient, Poster, Sun, Vaccine

A novel nectin-4 targeting monoclonal antibody with improved speed of internalization and a pharmacokinetic profile that can support Q3W dosing in the clinic.

Key Points: 
  • A novel nectin-4 targeting monoclonal antibody with improved speed of internalization and a pharmacokinetic profile that can support Q3W dosing in the clinic.
  • CRB-701 demonstrates statistically significant tumor growth inhibition in preclinical models that express mid- and high-levels of nectin-4, similar to EV.
  • CRB-701 has a longer half-life than EV and is being dosed on a Q3W schedule in the clinic.
  • “We are excited to share for the first time the pre-clinical validation of CRB-701 that supports its exploration in the clinic.

Pave America Strengthens national presence with additions of Kansas Asphalt and Central States Paving & Concrete

Retrieved on: 
Tuesday, October 10, 2023
Professional Services, Other Construction & Property, Finance, Construction & Property, Urban Planning, Landscape, Partnership, CSPC, Concrete, Partner, Growth, Maintenance, Road, Nightclub, North Central State Airport

Pave America, LLC (“Pave America”) has announced strategic partnerships with two leading industry players: Kansas Asphalt and Central States Paving & Concrete (“CSPC”).

Key Points: 
  • Pave America, LLC (“Pave America”) has announced strategic partnerships with two leading industry players: Kansas Asphalt and Central States Paving & Concrete (“CSPC”).
  • Kansas Asphalt, headquartered in Bucyrus, KS, is a leading provider of asphalt & concrete paving, maintenance & repair, and reconstruction services within Kansas, California, Texas, Ohio, and Iowa.
  • Central States Paving & Concrete is a leading provider of asphalt paving, concrete, sealcoating, striping, patching, and other parking lot maintenance services.
  • The CSPC management team will continue to lead the business going forward as a regional platform within Pave America.